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Background: The objective of this study was to investigate clinical manifestations of lower extremity edema (LEE)
in early ovarian cancer.
Methods: Patients with early ovarian cancer who underwent staging surgery between January 2001 and December
2010. Medical records for LEE and/or responses to the Gynecologic Cancer Lymphedema Questionnaire (GCLQ)
were evaluated.
Results: Patients had a median age of 46 years. Twenty-nine patients (40.8%) had past (13 patients, 44.8%) and/or
current patient-reported LEE (16 patients, 55.2%). Symptoms reported on the GCLQ in over 20% of respondents
were numbness, firmness/tightness, swelling, heaviness, limited movement of knee, and aching. GCLQ total
symptoms score was significantly higher in patients with current LEE. Most of the LEE (25/29, 86.2%) developed
within 12 months after surgery and LEE lasted more than 6 months in approximately two-thirds of the patients
(18/29, 62.1%). Only half of the patients (52.1%) indicated knowledge of lymphedema: 86.2% of LEE patients and
28.6% of patients with no LEE.
Conclusions: Although a significant proportion of patients with ovarian cancer have LEE after surgery, most are not
aware of lymphedema until they develop. Education and analyses for LEE and lymphedema are needed in patients
with ovarian cancer.
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Ovarian cancer is continuously increasing and the mor-
tality is high [1-3]. Current standard treatment is cytore-
ductive surgery including lymph node dissection (LND)
and chemotherapy. When there is no visible and palp-
able tumor in the peritoneal cavity during surgery, sys-
tematic pelvic and paraaortic LND is performed for
staging and debulking. For advanced bulky ovarian can-
cer, the high rate of recurrence, which affects approxi-
mately two-thirds of the patients, is a critical issue. On
the other hand, quality of life is one of the important
concerns for patients with early stage ovarian cancer.* Correspondence: gynlim@gmail.com; sypark.ncc@hotmail.com
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unless otherwise stated.Lower extremity edema (LEE) after surgical treatment
is one of the most important problems for women with
ovarian cancer. About 20% of ovarian cancer patients
develop LEE [4]. However, previous studies suffered
from critical limitations in terms of reproducibility be-
cause of the heterogeneous study cohort that included
patients with cervical, uterine, and vulvar cancer. Clin-
ical information, such as stage, was not included [4-6].
Records concerning LEE and lower leg lymphedema
(LLL) have been inconsistent. Generally, LEE is reported
by patients as a questionnaire response and LLL is for
the clinical diagnosis.
We investigated the clinical manifestations of LEE and
LLL in patients with early ovarian cancer and reviewed
the literature of LEE and LLL in patients with ovarian
cancer.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flowchart for identifying patient-reported lower
extremity edema in early ovarian cancer.
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After obtaining Institutional Review Board (National
Cancer Center, Korea) approval (NCCNCS-12-565), we
reviewed medical records of patients with early ovarian
cancer (FIGO stage I and II) at National Cancer Center
who underwent cytoreductive and staging surgery be-
tween January 2001 and December 2010. Inclusion cri-
teria were early stage epithelial ovarian cancer, no active
treatment, available telephone communication with pa-
tients, and ability and willingness to provide verbal in-
formed consent.
Medical records were reviewed. All patients who met
the inclusion criteria were contacted by a telephone call
by a investigator (JS LEE). The telephone interview ques-
tionnaire for LEE and gynecologic cancer lymphedema
questionnaire (GCLQ) took approximately 20–30 min to
complete. The questionnaire for LEE included onset,
severity, location, duration, and management. Patients
were also questioned concerning deep vein thrombosis
to exclude other causes of LEE. LEE was defined as
subjective edema of lower extremity based on patients’
complaint. LLL was defined based on a clinical diagnosis
of lymphedema by a physician.
A previously developed GCLQ was pilot tested with
patients with gynecologic cancers [7]. The GCLQ is sat-
isfactory to distinguish patients with and without LEE
[area under the curve (AUC), 0.95] and is easy to use.
The patient-self-reported symptom scores, GCLQ, in-
cluded seven symptom clusters: heaviness (item 14),
swelling (general; items 8, 9, 20), swelling (limb; items
18, 19), infection-related (items 10 [redness], 11 [blister-
ing], 13 [increased temperature in leg), aching (item 17),
numbness (items 7, 12, 15, 16), and physical functioning
(items 1–6) [7]. In the current study, Korean version of
GCLQ (GCLQ-K) which was developed after minimal
modifications from original GCLQ by our research team
and showed high internal consistency and reproducibil-
ity was used [8]. In addition, ever or current LEE, loca-
tion and onset of LEE, and any symptoms related to LEE
were evaluated. Past LEE was an experience of LEE dur-
ing a certain period and no current LEE. Current LEE
was the existence of LEE at the time of survey irrespect-
ive of the onset of LEE. Ever LEE included the entire
past and current LEE.
Results
Of 96 patients with early epithelial ovarian cancer, 71 pa-
tients were contacted by telephone and their medical re-
cords were available (Figure 1). Characteristics of
evaluable patients for LEE (n = 71) including age, body
mass index, type of disease, FIGO stage, histology,
CA125, and LN dissection are presented in Table 1.
Most patients had ovarian cancer (n = 69) and the
remaining two patients had tubal cancer. Fifty-two and19 patients were identified and comprised the current
FIGO stage I and II groups, respectively. The median
age of the patients was 46 years (range, 22–65 years).
Fifteen patients (21.1%) had serous histology. The
remaining 56 patients (78.9%) had non-serous histology:
mucinous (n = 11, 15.5%), endometrioid (n = 14, 19.7%),
clear cell carcinoma (n = 15, 21.1%), transitional cell (n
= 3, 4.2%), and other including mixed carcinoma (n = 13,
18.3%). Serum CA-125 was checked preoperatively in 68
patients (95.8%); 39 patients (57.4%) had elevated serum
CA-125 level (≥35 U/mL). The median value of serum
CA-125 was 42 U/mL (range, 1.9-4389 U/mL). Sixty-one
patients (85.9%) received chemotherapy, which consisted
of paclitaxel and carboplatin in 39 patients, paclitaxel
and cisplatin in 20 patients, and cyclophosphamide and
cisplatin (+Adriamycin) in two patients.
Of 71 evaluable patients, 29 (40.8%) patients had or
previously had LEE. Of 29 patients, 16 patients (55.2%)
had current LEE and 13 patients (44.8%) had past LEE.
Clinical LLL was diagnosed in nine patients with ovarian
cancer. All nine patients with a clinical diagnosis of LLL
were included in the group of patients with LEE. One
patient did not remember the exact onset time and end-
point of LEE. Onset time and end-point of LEE could
not be precisely identified in one and five patients, re-
spectively. Accordingly, the duration of LEE was not de-
finitive in seven patients. Figure 2 depicts the onset and
duration of LEE. In the 27 patients with a clear onset of
LEE, LEE occurred within 1 month after LND in 17
(63%), within 3 months after LND in five (18.5%), within
6 months after LND in two (7.4%), and within 12 months
after LND in one (3.7%). In two patients, LEE developed
51 and 72 months after LND. More than half of the pa-
tients (16/29, 55.2%) had LEE at time of completing the
questionnaire. In the 22 patients with a clear duration of
LEE, the duration of LEE was within 6 months in six
Table 1 Patients characteristics in early ovarian cancer
(n = 71)
Characteristics Total
Age (year) at time of operation
Median (range) 46 (22–65)
Body weight (kg) 55.6 (42–78)
Height (cm) 158 (144–165)
Body mass index 23 (15.6-34.6)
Type of disease, n (%)
Ovarian cancer 69 (97.2%)
Tubal cancer 2 (2.8%)











Clear cell 15 (21.1%)
Transitional cell 3 (4.2%)
Others including mixed 13 (18.3%)
CA125 (U/mL)*
Median (range) 42 (1.9–4389)
≥35, n (%) 39 (57.4%)
LN dissection, n (%) 69 (97.2%)
Number of LN dissected
Median (range) 22 (3–98)
Chemotherapy 61 (85.9%)
FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node.
*CA125 was available in 68 women.
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(22.7%), and more than 60 months in nine (40.9%).
Table 2 summarizes the patient-reported GCLQ data
measured as “present with the past 4 weeks”. Symptoms in
order of frequency were numbness (40.8%), firmness/tight-
ness (22.5%), swelling (22.5%), heaviness (22.5%), limited
movement of knee (21.1%), aching (21.1%), leg or foot feel
weakness (18.3%), stiffness (15.5%), increased temperature
in the leg (12.7%), limited movement of ankle (11.3%), and
limited movement of foot (11.3%). The GCLQ score was
significantly higher in patients with ever LEE compared to
no LEE (p < 0.01).
Of the 29 patients with ever LEE, 10 (34.5%) patients
made efforts to reduce the LEE by leg elevation using apillow (n = 8), remedial exercise (n = 3), and other per-
sonalized exercise (n = 1). Of the 71 patients with early
ovarian cancer and LND, only 52.1% (37/71) of the pa-
tients replied that they had general knowledge for LLL:
86.2% (25/29) and 28.6% (12/42) in patients with ever
LEE and no LEE, respectively.
Discussion
This is the first report to our knowledge that specifically
addresses the incidence and duration of LEE in the ovar-
ian cancer. The prevalence of ever LEE was 40.8, past was
18.3, and current was 22.5%. Most of the LEE (86.2%, 25/29)
developed within 12 months after surgery and LEE lasted
more than 6 months in approximately two-thirds of the
patients (62.1%, 18/29).
The onset of LEE is consistent with previous results
[6,9]. LEE and LLL are an important problem for ovarian
cancer patients, because the current standard surgical
treatment of ovarian cancer include lymph node dissec-
tion [10]. However, the real clinical impact of LEE and
LLL on quality of life has not been specifically investi-
gated (Table 3). We routinely offer education concerning
the risk of lymphedema, lymphocyst, and dermatolym-
phangitis, and guidelines to prevent LLL in our routine
clinical practice. More recently, we instituted a policy
where all patients scheduled to undergo LND watch a
video of exercise for lymphedema before surgery. How-
ever, only half of the patients with early ovarian cancer
responded that they are aware of LLL. It seems that
knowledge for lymphedema might be acquired post-LEE,
considering the appreciable difference of knowledge de-
pending on the existence of LEE (86.2% vs. 28.6%). Ac-
tion and study for effective health care provider-patient
communication is needed to narrow the gap between
health care provider efforts and patient knowledge [11].
From two randomized trials of LND, the risk of LLL
significantly increased in a group with systematic LND
compared to a group with lymph node sampling in early
(5.8% vs. 0%) and advanced (6.5% vs. 0%) ovarian cancer
[12,13]. The site of the lymph node dissected is an im-
portant factor related to LEE/LLL. Paraaortic LND (25.8
vs. 31.7%, p = 0.158) does not increase the risk of LLL
[9]. The prevalence of LEE was significantly elevated
after LND including the groin: 18.0% for pelvis and para-
aortic; 20.2% for pelvis only; 50% for pelvis and groin,
and 62.2% for groin only [6]. Groin and pelvis is the crit-
ical area for LEE/LLL. Paraaortic LND is not a risk fac-
tor [5,6]. In this study, most of women with early
ovarian cancer underwent systematic LND in the pelvis
and paraaortic area. Retroperitoneal closure was investi-
gated and found not to be a risk factor of LEE despite a
significant numerical difference (41.7% vs. 22.2%) [14].
Because of the small number of patients (n = 21), further
studies are needed to confirm this. In this study, only
Figure 2 Onset and duration of lower extremity edema in early ovarian cancer. One line is omitted because of obscure onset and duration
in one patient.
Table 2 Frequency on the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) items in early ovarian cancer
(n = 71)
Variables
GCLQ items SC GCLQ lower extremity lymphedema
symptoms items
Total n (%) Past LEE n (%) Current LEE n (%) Ever LEE n (%) No LEE n (%)
15 N Experienced numbness 29 (40.8%) 4 (5.6%) 8 (11.3%) 12(16.9%) 17 (23.9%)
12 N Experienced firmness/tightness 16 (22.5%) 1 (1.4%) 8 (11.3%) 9 (12.7%) 7 (9.9%)
8 SW Experienced swelling 16 (22.5%) 2 (2.8%) 12 (16.9%) 14(19.7%) 2 (2.8%)
14 H Experienced heaviness 16 (22.5%) 2 (2.8%) 7 (9.9%) 9 (12.7%) 7 (9.9%)
2 PF Limited movement of your knee 15 (21.1%) 2 (2.8%) 4 (5.6%) 6 (8.5%) 9 (12.7%)
17 A Experienced aching 15 (21.1%) 0 (0.0%) 7 (9.9%) 7 (9.9%) 8 (11.3%)
6 PF Leg or foot feel weak 13 (18.3%) 2 (2.8%) 4 (5.6%) 6 (8.5%) 7 (9.9%)
16 N Experienced stiffness 11 (15.5%) 1 (1.4%) 3 (4.2%) 4 (5.6%) 7 (9.9%)
13 INF Experienced increased temperature in the leg 9 (12.7%) 0 (0.0%) 3 (4.2%) 3 (4.2%) 6 (8.5%)
3 PF Limited movement of your ankle 8 (11.3%) 1 (1.4%) 3 (4.2%) 4 (5.6%) 4 (5.6%)
4 PF Limited movement of your foot 8 (11.3%) 1 (1.4%) 4 (5.6%) 5 (7.0%) 3 (4.2%)
19 LSW Experienced groin swelling 6 (8.5%) 0 (0.0%) 4 (5.6%) 4 (5.6%) 2 (2.8%)
1 PF Limited movement of your hip 5 (7.0%) 1 (1.4%) 0 (0.0%) 1 (1.4%) 4 (5.6%)
5 PF Limited movement of your toe 5 (7.0%) 1 (1.4%) 2 (2.8%) 3 (4.2%) 2 (2.8%)
10 INF Experienced redness 4 (5.6%) 1 (1.4%) 2 (2.8%) 3 (4.2%) 1 (1.4%)
7 N Experienced tenderness 3 (4.2%) 0 (0.0%) 3 (18.8%) 3 (4.2%) 0 (0.0%)
9 SW Experienced swelling with pitting 3 (4.2%) 1 (1.4%) 2 (2.8%) 3 (4.2%) 0 (0.0%)
18 LSW Experienced hip swelling 3 (4.2%) 0 (0.0%) 1 (1.4%) 1 (1.4%) 2 (2.8%)
11 INF Experienced blistering 2 (2.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (2.8%)
20 SW Experienced pockets of fluid 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
A, ache; H, heaviness; INF, infection; LEE, lower extremity edema; LLL, lower leg lymphedema; LSW, limb swelling; N, neuropathy; n, number; PF, physical function;
SC, symptoms cluster; SW, swelling general.
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Table 3 Incidence and risk factors of edema and/or lymphedema of lower leg after treatment of ovarian cancer




Stage Diagnostic criteria Incidence (%) Risk factor
for LEE/LLL
Comment
Ryan M. 2003 CQ & MRR 141 (487) NA · Diagnosed LLL · 7.1% (10/141) in OC – · MTFOTL: 3, 6, 12, and 60 months in 53,
18, 13, and 16% of the patients with GC.
· 18.3% (89/487) in all GC
· 62.2% (28/45) after GLND · Highest rate of LLL after GLND (50–62.2%).
· 50.0% (47/233) after
GLND + PLND
Panici PB. 2005 Multi-center
Italian RCT
427 III, 406 (95.1%) · Diagnosed LLL · 6.5% (14/216) vs. 0%
(0/211) in SL vs. LNS
· SL compared to LNS · Improvement of SL on PFS, but not OS.
IV, 21 (4.9%)
Magginoi A. 2006 Multi-center
Italian RCT
268 I, 192 (72.7%) · Diagnosed LLL · 5.8% (8/138) vs. 0%
(0/130) in SL vs. LNS
· SL compared to LNS · No improvement of SL on PFS and OS.
II, 72 (27.3%)
Beesley V. 2007 PRO via mail 234 (802) NA · PRO - LEE · LEE, 15.8% (37/234) – · Lowest incidence (4.7%) of LLL among GC
· Diagnosed LLL · LLL, 4.7% (11/234) · BMI is not risk factor.
Tanaka T. 2007 CQ & MRR 21 (184) I–II, 17 (81%) · PRO - LEE · 41.7% (5/12) in RC vs. – · RC is not risk factor. This should be
investigated again in larger number
of patients.III–IV, 4 (19%) · 22.2% (2/9) in non-RC
Tada H. 2009 Multi-center
Japanese
Retrospective
135 (694) I–II, 75 (55.6%) · Diagnosed &
symptomatic LLL
· 20.7% (28/135) · RT, OR 1.79
(95%CI, 1.20-2.68)
· MTFOTL: 4.6 (0.1–40.2) months
· LLL, 25.8 vs. 31.7% in PALND(−) vs. (+)III–IV, 60 (44.4%)
Matsuo K. 2011 Retrospective 276 I–II, 43 (15.6%) · MRR · LEE, 6.5% (18/276) – · LEE at initial diagnosis is an important
on PFS (4.9 vs. 15.3 months) and
OS (5.9 and 49.1 months).III–IV, 233 (84.5%)
· LEE is the 14th symptoms.
Karlan BY. 2012 RCT 161 Recurrent OC · Peripheral edema · LEE, 51-71% vs. 22% in
AMG 386* vs. Control
AMG386 administered
patients
· LEE, 51 & 71% (AMG 386 3 & 10 mg/kg
QW with paclitaxel QW) vs. 22% in AMG
386* vs. Control (weekly paclitaxel
(80 mg/m2 QW)
Achouri A. 2012 Retrospective 36 (88) NA · Diagnosed LLL · 5.6% (2/36) · Postoperative drainage,
OR 0.13 (95%CI, 0.02-0.69)
· Incidence of LLL, 11.4% and 23.5% in
EC and CC.
· BMI, surgical approach (laparoscopy
and laparotomy), PALND, SPOL, number





















CQ & MRR 71 I, 52 (73.3%) · PRO - LEE · 40.8% (29/71) – · MTFOTL: <1, 3, 6, and 12 months
in 63,18.5, 7.4, and 3.7%
II, 19 (26.7%)
· Median duration of LEE: <6, 12, 60,
and ≥60 in 27.3, 9.1, 22.7, and 40.9%
BMI, body mass index; CC, cervical cancer; CQ, cross-sectional questionnaire; EC, endometrial cancer; GC, gynecologic cancer; GLND, groin lymph node dissection; LEE, lower extremity edema; LLL, lower leg
lymphedema; LND, lymph node dissection; LNS, lymph node sampling; MRR, medical record review; MTFOTL, median time from operation to lower extremity edema; N, number; NA, not available; OC, ovarian cancer;
OS, overall survival; PALN, paraaortic lymph node; PALND, paraaortic lymph node dissection; PFS, progression free survival; PLN, pelvic lymph node; PLND, pelvic lymph node dissection; PRO, patient reported outcomes;
QW, once weekly; RC, retroperitoneal closure; RCT, randomized trial; RT, radiotherapy; SL, systemic pelvic and aortic lymph node dissection; SPOL, symptomatic postoperative lymphocele.
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with ovarian cancer. The exact role of retroperitoneal
closure should be confirmed in a large patient cohort.
Body mass index, surgical approach (laparotomy vs.
laparoscopy), and symptomatic postoperative lymphocele
are not risk factors of LEE/LLL [4,5].
Two randomized trials analyzed survival for systematic
LND in ovarian cancer [12,13]. In one study, systemic
LND improved only progress-free survival in advanced
ovarian cancer [13]. In early ovarian cancer, there is no
survival benefit from systematic LND [12]. The power was
80% implying insufficient power to exclude clinically im-
portant effects of systematic LND on survival [12]. LND is
still one of the standard staging and cytoreductive surgical
procedures. At this point, gynecologic oncologists, med-
ical oncologists who perform adjuvant chemotherapy, and
patients with ovarian cancer should be aware of the pat-
tern of LEE/LEE [10]. Figure 2 illustrates the pattern of
LEE after cytoreductive surgery and adjuvant chemother-
apy, in close agreement with previous studies [6,9]. We
first investigated the duration of LEE (Figure 2). This in-
formation should be discussed with patients before LND.
On the other hand, Matsuo et al. reported that LEE at
time of the initial diagnosis of ovarian cancer is a strong
prognostic indicator of PFS (4.9 vs. 15.3 months, p < 0.01)
and overall survival (5.9 and 49.1 months, p < 0.01) [15].
Previously, we reported that LEE as a clinical manifest-
ation of deep vein thrombosis, suggesting disease burden,
might be a poor prognostic marker in survival of ovarian
cancer [16,17]. In the current study, 41.4% (12/29) of the
patients responded that they had LEE immediately after
surgery. However, the prognostic role of LEE is difficult to
analyze because of the limited disease failure in early ovar-
ian cancer. Theoretically, LEE could easily develop in pa-
tients with deep vein thrombosis from extensive disease
and compression of lymphatic vessel from bulky lymph
node metastasis. The prognostic role of LEE in ovarian
cancer should be investigated.
The limitations of this study are that it was not a pro-
spective study, that LEE/LLL related events like postoper-
ative lymphocyst and/or dermatolymphangitis were not
analyzed, and the lack of confirmation of the relationship
of LEE and LLL because a significant portion of the pa-
tients in this study visited only annually. And there is a
possibility of bias because this was a retrospective and
cross-sectional study. The strengths of this study are the
homogenous patient cohort in terms of stage, surgical
principle, and adjuvant chemotherapy; the use of a vali-
dated questionnaire [7]; and the clear description of the
duration of LEE.
Conclusions
In the current study, significant numbers of patients
with ovarian cancer have LEE after primary treatment ofovarian cancer. However, most of them were unfamiliar
with lymphedema until they actually develop LEE.
Therefore, preoperative and postoperative counseling
and education for prevention and early sign of LEE/LLL
should be provided to the patients who will undergo
LND. And prospective studies for effective educational
interventions on LEE/LLL are needed in patients with
ovarian cancer.
Abbreviations
FIGO: International Federation of Gynecology and Obstetrics; LEE: Lower
extremity edema; LLL: Lower leg lymphedema; LND: Lymph node dissection.
Competing interests
No potential competing interest are disclosed.
Authors’ contributions
MCL and SYP managed the overall project. All authors participated in
research design and contributed to the writing and revising of the
manuscript. JSL surveyed and collected all data. BHN performed primary
analysis of the data. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the Korean National Cancer Center
(1210510).
Author details
1Center for Uterine Cancer, Research Institute and Hospital, National Cancer
Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si 410-769, Gyeonggi-do, Republic
of Korea. 2Gynecologic Cancer Branch, Research Institute and Hospital,
National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si 410-769,
Gyeonggi-do, Republic of Korea. 3Biostatistics Biometric Research Branch,
Research Institute and Hospital, National Cancer Center, 323, Ilsan-ro,
Ilsandong-gu, Goyang-si 410-769, Gyeonggi-do, Republic of Korea.
Received: 21 January 2014 Accepted: 3 March 2014
Published: 7 March 2014
References
1. Lim MC, Moon EK, Shin A, Jung KW, Won YJ, Seo SS, Kang S, Kim JW,
Kim JY, Park SY: Incidence of cervical, endometrial, and ovarian cancer in
Korea, 1999–2010. J Gynecol Oncol 2013, 24(4):298–302.
2. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS: Cancer statistics in
Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res
Treat: J Korean Cancer Assoc 2013, 45(1):1–14.
3. Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL, Cheng WF, Lai MS:
Trends in incidence and survival outcome of epithelial ovarian cancer:
30-year national population-based registry in Taiwan. J Gynecol Oncol
2013, 24(4):342–351.
4. Beesley V, Janda M, Eakin E, Obermair A, Battistutta D: Lymphedema after
gynecological cancer treatment: prevalence, correlates, and supportive
care needs. Cancer 2007, 109(12):2607–2614.
5. Achouri A, Huchon C, Bats AS, Bensaid C, Nos C, Lecuru F: Postoperative
lymphocysts after lymphadenectomy for gynaecological malignancies:
preventive techniques and prospects. Eur J Obstet Gynecol Reprod Biol
2012, 161(2):125–129.
6. Ryan M, Stainton MC, Slaytor EK, Jaconelli C, Watts S, Mackenzie P:
Aetiology and prevalence of lower limb lymphoedema following
treatment for gynaecological cancer. Aust N Z J Obstet Gynaecol 2003,
43(2):148–151.
7. Carter J, Raviv L, Appollo K, Baser RE, Iasonos A, Barakat RR: A pilot study
using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a
clinical care tool to identify lower extremity lymphedema in gynecologic
cancer survivors. Gynecol Oncol 2010, 117(2):317–323.
8. Lim MC, Lee JS, Joo J, Park K, Yoo HJ, Seo SS, Kang S, Chung SH, Park SY:
Development and evaluation of the korean version of the gynecologic
cancer lymphedema questionnaire in gynecologic cancer survivors.
Gynecol Oncol 2014. Article in press, http://dx.doi.org/10.1016/j.
ygyno.2014.01.040.
Lim et al. Journal of Ovarian Research 2014, 7:28 Page 8 of 8
http://www.ovarianresearch.com/content/7/1/289. Tada H, Teramukai S, Fukushima M, Sasaki H: Risk factors for lower limb
lymphedema after lymph node dissection in patients with ovarian and
uterine carcinoma. BMC Cancer 2009, 9:47.
10. Schorge JO, Eisenhauer EE, Chi DS: Current surgical management of
ovarian cancer. Hematol Oncol Clin North Am 2012, 26(1):93–109.
11. Stewart MA: Effective physician-patient communication and health
outcomes: a review. CMAJ 1995, 152(9):1423–1433.
12. Maggioni A, Benedetti Panici P, Dell'Anna T, Landoni F, Lissoni A, Pellegrino A,
Rossi RS, Chiari S, Campagnutta E, Greggi S, Angioli R, Manci N, Calcaqno M,
Scambia G, Fossati R, Floriani I, Torri V, Grassi R, Manqioni C: Randomised
study of systematic lymphadenectomy in patients with epithelial
ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006,
95(6):699–704.
13. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E,
Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G,
Dell’Anna T, Fossati R, Floriani I, Rossi RS, Grassi R, Favalli G, Raspagliesi F,
Giannarelli D, Martella L, Manqioni C: Systematic aortic and pelvic
lymphadenectomy versus resection of bulky nodes only in optimally
debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer
Inst 2005, 97(8):560–566.
14. Tanaka T, Ohki N, Kojima A, Maeno Y, Miyahara Y, Sudo T, Takekida S,
Yamaguchi S, Sasaki H, Nishimura R: Radiotherapy negates the effect of
retroperitoneal nonclosure for prevention of lymphedema of the legs
following pelvic lymphadenectomy for gynecological malignancies:
an analysis from a questionnaire survey. Int J Gynecol Cancer 2007,
17(2):460–464.
15. Matsuo K, Ahn EH, Prather CP, Eno ML, Im DD, Rosenshein NB: Patient-reported
symptoms and survival in ovarian cancer. Int J Gynecol Cancer 2011,
21(9):1555–1565.
16. Lim MC, Park SH, Park SY: Ovarian clear cell carcinoma: high risk of
venous thromboembolism. Gynecol Oncol 2010, 118(3):317. author reply
317–318.
17. Lim MC, Lee HS, Kang S, Seo SS, Lee BY, Park SY: Minimizing tumor burden
by extensive cytoreductive surgery decreases postoperative venous
thromboembolism in ovarian clear cell carcinoma. Arch Gynecol Obstet
2010, 281(2):329–334.
doi:10.1186/1757-2215-7-28
Cite this article as: Lim et al.: Lower extremity edema in patients with
early ovarian cancer. Journal of Ovarian Research 2014 7:28.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
